Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP-G2-044 Monotherapy and Combination Therapy in Advanced or Metastatic Solid Tumors
NCT05023486Phase 2Completed
- Sponsor
- Novita Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Prilukae in solid tumor (2 arms), sponsored by Novita Pharmaceuticals. Primary endpoints: Recommended Phase 2 Dose at 9 months, Treatment Emergent Adverse Events and 1 more. Started Dec 2021; status: completed.
02
Drugs
Prilukae
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05023486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023486.